Ayhanım Elif MÜDERRİSOĞLU, Betül Rabia ERDOĞAN, Zeynep Elif YEŞİLYURT, Ceren UYAR BOZTAŞ, İrem KARAÖMERLİOĞLU, Vecdi Melih ALTAN, Ebru ARIOĞLU İNAN

Effects of sitagliptin on ß-adrenoceptor mediated relaxation in streptozotocin-diabetic rat aorta

Background/aim: Dipeptidyl peptidase-4 (DPP4) inhibitors, a class of oral antidiabetic drugs, have been shown to be protective on the vascular system because of their antiinflammatory, antiatherosclerotic, and vasodilatory effects. ß2 -adrenoceptors (ß2 -ARs) mediate the vasorelaxation in the aorta. However, ß3 -adrenoceptor-mediated relaxation has not been studied in diabetic aorta yet. Thus, we aimed to study the effect of sitagliptin treatment on ß2 - and ß3 -adrenoceptor-mediated relaxations in the diabetic rat aorta. Materials and methods: Eight-week old Sprague Dawley rats were divided into three groups: control, diabetic, sitagliptin treated diabetic. Diabetes was induced by injection of streptozotocin (35 or 40 mg/kg, intraperitoneally). After 10 weeks of diabetes, some of the diabetic rats were treated with sitagliptin (orally, 10mg/kg/day). ß2 - and ß3 -AR-mediated relaxation responses were evaluated by using isoprenaline and CL 316,243, respectively. ß3-AR-mediated relaxation experiments were repeated in presence of L-NAME. Western blotting and immunohistochemistry were performed to determine the abundance of ß3 -adrenoceptor and endothelial nitric oxide synthase (eNOS). Results: The isoprenaline-mediated relaxation response was impaired in the diabetic group and sitagliptin treatment did not improve it. There was no significant change in CL316,243 mediated-relaxation or protein expression of ß3 -ARs among the groups. However, the ratio of phosphorylated eNOS/NOS protein was increased markedly in the sitagliptin treated group, which points the stimulating effect of this drug towards the eNOS pathway. Conclusion: Our results indicate that sitagliptin treatment does not alter ß-AR-mediated relaxation in streptozotocin-diabetic rat aorta; however, it significantly stimulates the eNOS pathway. Future studies are needed to clarify the relationship between the eNOS pathway and DPP-4 inhibition.Key words: ß-adrenoceptors, aorta, streptozotocin induced diabetes, sitagliptin, endothelial nitric oxide synthase

PDF

___

1. Shi Y, Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. Journal of Diabetes 2017; 9 (5): 434- 449. doi: 10.1111/1753-0407.12521
2. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002; 105 (5): 546-549. doi: 10.1161/hc0502.104540
3. Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein e-deficient mice. Journal of the American College of Cardiology 2012; 59 (3): 265-276. doi: 10.1016/j.jacc.2011.07.053
4. Shah Z, Kampfrath T, Deiuliis J, Zhong J, Pineda C et al. Longterm dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011; 124 (21): 2338-2349. doi: 10.1161/CIRCULATIONAHA.111.041418
5. Vellecco V, Mitidieri E, Gargiulo A, Brancaleone V, Matassa D et al. Vascular effects of linagliptin in non-obese diabetic mice are glucose-independent and involve positive modulation of the endothelial nitric oxide synthase (enos)/caveolin-1 (cav-1) pathway. Diabetes, Obesity & Metabolism 2016; 18 (12): 1236- 1243. doi: 10.1111/dom.12750
6. Shah Z, Pineda C, Kampfrath T, Maiseyeu A, Ying Z et al. Acute DPP-4 inhibition modulates vascular tone through GLP1 independent pathways. Vascular Pharmacology 2011; 55 (1- 3): 2-9. doi: 10.1016/j.vph.2011.03.001
7. Tang ST, Su H, Zhang Q, Tang HQ, Wang CJ et al. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase. International Journal of Molecular Medicine 2016; 37 (6): 1558-1566. doi: 10.3892/ ijmm.2016.2578
8. Li H, Seo MS, An JR, Jung HS, Ha KS et al. Dipeptidyl peptidase-4 inhibitor sitagliptin induces vasorelaxation via the activation of Kv channels and PKA. Toxicology and Applied Pharmacology 2019; 384: 114799. doi: 10.1016/j.taap.2019.114799
9. Trochu JN, Leblais V, Rautureau Y, Beverelli F, Le Marec H et al. Beta 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta. British Journal of Pharmacology 1999; 128 (1): 69-76. doi: 10.1038/sj.bjp.0702797
10. Flacco N, Segura V, Peraz-Aso M, Estrada S, Seller JF et al. Different ß-adrenoceptor subtypes coupling to camp or NO/ cGMP pathways: implications in the relaxant response of rat conductance and resistance vessels. British Journal of Pharmacology 2013; 169 (2): 413-425. doi: 10.1111/bph.12121
11. Brahmadevara N, Shaw AM, MacDonald A. Evidence against ß3-adrenoceptors or low affinity state of ß1-adrenoceptors mediating relaxation in rat isolated aorta. British Journal of Pharmacology 2003; 138 (1): 99-106. doi: 10.1038/sj.bjp.0705017
12. Pieper GM, Siebeneich W. Oral administration of the antioxidant, N-acetylcysteine, abrogates diabetes-induced endothelial dysfunction. Journal of Cardiovascular Pharmacology 1998; 32 (1): 101-105. doi: 10.1097/00005344-199807000-00016
13. Roghani-Dehkordi F, Roghani M, Baluchnejadmojarad T. Diosgenin mitigates streptozotocin diabetes-induced vascular dysfunction of the rat aorta: the involved mechanisms. Journal of Cardiovascular Pharmacology 2015; 66 (6): 584-592. doi: 10.1097/FJC.0000000000000308
14. Zeydanli EN, Turan B. Omega-3E treatment regulates matrix metalloproteinases and prevents vascular reactivity alterations in diabetic rat aorta. Canadian Journal of Physiology and Pharmacology 2009; 87 (12): 1063-1073. doi: 10.1139/Y09-112
15. Lu CW, Lin Y, Lei YP, Wang L, He ZM et al. Pyrrolidine dithiocarbamate ameliorates endothelial dysfunction in thoracic aorta of diabetic ratsby preserving vascular ddah activity. Plos One 2017; 12 (7): e0179908. doi: 10.1371/journal.pone.0179908
16. Zeydanli EN, Bilginoglu A, Tanriverdi E, Gurdal H, Turan B. Selenium restores defective beta-adrenergic receptor response of thoracic aorta in diabetic rats. Molecular and Cellular Biochemistry 2010; 338 (1-2): 191-201. doi: 10.1007/s11010-009- 0353-5
17. Lee TM, Chen WT , Chang NC. Sitagliptin decreases ventricular arrhythmias by attenuated glucose-dependent insulinotropic polypeptide (GIP)-dependent resistin signalling in infarcted rats. Bioscience Reports 2016; 36 (2): e00307. doi: 10.1042/ BSR20150139
18. Liu C, Sun J, Xue F, Yi Y, Han A. Effect of 3,4-dihydroxyacetophenone on endothelial dysfunction in streptozotocin-induced rats with type 2 diabetes. Journal of Cardiovacular Pharmacology 2015; 65 (1): 22-27. doi: 10.1097/FJC.0000000000000158
19. Reimer RA, Grover GJ, Koetzner L, Gahler RJ, Juneja P et al. Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese zucker rats. The Journal of Nutrition 2012; 142 (10): 1812-1819. doi: 10.3945/jn.112.163204
20. Vaghasiya J, Sheth N, Bhalodia Y, Manek R. Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. Regulatory Peptides 2011; 166 (1-3): 48-54. doi: 10.1016/j.regpep.2010.08.007
21. Wang H, Zhou Y, Guo Z, Dong Y, Xu J et al. Sitagliptin attenuates endothelial dysfunction of zucker diabetic fatty rats:implication of the antiperoxynitrite and autophagy. Journal of Cardiovascular Pharmacology and Therapeutics 2018; 23 (1): 66-78. doi: 10.1177/1074248417715001
22. Silva Junior WS, Godoy-Matos AF, Kraemer-Aguiar LG. Dipeptidyl peptidase 4: a new link between diabetes mellitus and atherosclerosis? Biomedical Research International 2015; 2015: 816164. doi: 10.1155/2015/816164
23. Rautureau Y, Toumaniantz G, Serpillon S, Jourdon P, Trochu JN et al. Beta 3-adrenoceptor in rat aorta: molecular and biochemical characterization and signalling pathway. British Journal of Pharmacology 2002; 137 (2): 153-161. doi: 10.1038/ sj.bjp.0704867
24. Arioglu-Inan E, Ozakca I, Kayki-Mutlu G, Sepici-Dincel A, Altan VM. The role of insulin-thyroid hormone interaction on β-adrenoceptor-mediated cardiac responses. European Journal of Pharmacology 2013; 718 (1-3): 533-543. doi: 10.1016/j. ejphar.2013.06.021
25. Kayki-Mutlu G, Arioglu-Inan E, Ozakca I, Ozcelikay AT, Altan VM. β3-adrenoceptor-mediated responses in diabetic rat heart. General Physiology and Biophysics 2014; 33 (1): 99-109. doi: 10.4149/gpb_2013065
26. Kayki Mutlu G, Arioglu Inan E, Karaomerlioglu I, Altan VM, Yersal N et al. Role of the β3-adrenergic receptor subtype in catecholamine-induced myocardial remodeling. Molecular and Cellular Biochemistry 2018; 446 (1-2): 149-160. doi: 10.1007/s11010-018-3282-3
27. Dinçer UD, Bidasee KR, Güner S, Tay A, Ozçelikay AT et al. The effect of diabetes on expression of β1 -, β2-, and β3-adrenoreceptors in rat hearts. Diabetes 2001; 50 (2): 455-461. doi: 10.2337/diabetes.50.2.455
28. Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C et al.. Upregulation of ß3 -adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 2001; 103 (12): 1649-1655. doi: 10.1161/01. cir.103.12.1649
29. Ozakca I, Arioglu-Inan E, Esfahani H, Altan VM, Balligand J-L et al. Nebivolol prevents desensitization of β-adrenoceptor signaling and induction of cardiac hypertrophy in response to isoprenaline beyond β1-adrenoceptor blockage. American Journal of Physiology. Heart and Circulatory Physiology 2013; 304 (9): 1267-1276. doi: 10.1152/ajpheart.00352.2012
30. Ding L, Zhang J. Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacologica Sinica 2012; 33 (1): 75-81. doi: 10.1038/ aps.2011.149
31. Hu Y, Liu H, Simpson RW, Dear AE. GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells. Molecular Biology Reports 2013; 40 (3): 2273-2279. doi: 10.1007/s11033- 012-2290-8